Latest Funding And Capital Raising News

Orezone Gold Corporation reports solid Q2-2025 results from its Bomboré Gold Mine, maintaining production guidance and progressing major expansion projects on schedule and budget.

Silver Mines Limited has launched a $3 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy shares at a 16.3% discount. The offer, which opened on 13 August 2025, supports key development and exploration projects.

AKORA Resources has launched a $2.91 million capital raising through a placement and entitlement offer to fund critical development milestones at its Bekisopa Iron Ore Project in Madagascar.

Macro Metals Limited has successfully raised A$2 million through a share placement, positioning itself to accelerate exploration and expand its mining services operations.

Larvotto Resources delivers a robust Definitive Feasibility Study for its Hillgrove Antimony-Gold Project, backed by $165 million in fresh funding and regulatory approvals, targeting production in Q2 2026.

Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.

Horizon Gold has completed a major drilling campaign at its Gum Creek Gold Project, delivering high-grade gold intercepts and advancing its feasibility study on track for early 2026. A $12 million capital raise post-quarter end aims to fund further exploration and project development.

Carawine Resources advances exploration planning at Paterson and other projects while facing a pivotal court decision on shareholder compulsory acquisition and securing a $1.7 million loan to sustain operations.

360 Capital Mortgage REIT has successfully raised $6.4 million through an additional placement of over one million new units, aiming to expand its mortgage loan portfolio and enhance trading liquidity.

Hazer Group has successfully raised $10.7 million through a combination of a share placement and a share purchase plan, positioning the company to advance its innovative clean hydrogen and graphite production technology.

Prescient Therapeutics has extended its Share Purchase Plan closing date to 22 July 2025, aiming to raise up to A$7 million to advance its targeted cancer therapy PTX-100 through Phase 2 clinical trials.

Spacetalk Ltd has raised $3 million through convertible notes from its largest shareholder and converted $1 million of secured debt, positioning the company for international growth and new product development.